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Summary The relationships between response to chemotherapy of advanced breast cancer and the
histological type, grade, elastosis content and DNA ploidy of the primary tumours were examined using
paraffin-embedded tissue derived from 125 patients. Higher response rates were seen amongst tumours with a
high elastosis content and those that were diploid. However, selection of patients with advanced breast cancer
for chemotherapy will not be assisted significantly by an assessment of these features in the primary tumour.
Objective regression of advanced breast cancer can be
achieved in approximately 50% of patients treated by
chemotherapy, but there is no reliable method of predicting
which patients will benefit. In previous studies we
demonstrated an association between certain pathological
features and response to endocrine therapy. Patients with
well-differentiated carcinomas or those containing abundant
elastosis showed a significantly higher frequency of response
(Millis et al., 1981; Masters et al., 1986). In addition, in
some studies, DNA ploidy is associated with oestrogen
receptor status and with histological differentiation (see
review by Friedlander et al., 1984) and might provide an
objective and reproducible alternative to histological grading.
The purpose of this study was to determine whether
histological grade, elastosis and DNA ploidy are related to
response to chemotherapy.
Materials and methods
One hundred and twenty-five patients were studied. The
criteria for eligibility were (a) no prior chemotherapy and (b)
availability of sections from the primary tumour for
histological evaluation. Response to the first chemotherapy
regimen for advanced disease, either adriamycin alone or
with vincristine (Steiner et al., 1983) was assessed according
to UICC criteria (Hayward et al., 1977) as objective
regression (complete or partial response) or no response (no
change or progressive disease). Histological grade was
assessed in infiltrating ductal tumours using the classification
of Bloom and Richardson (1957), as grade 1 (well
differentiated), grade 2 (moderately differentiated) or grade 3
(poorly differentiated). Fifteen lobular tumours were not
graded. Elastosis was demonstrated using orcein stained
sections, available from 106 cases, and assessed as previously
described (Masters et al., 1979), and classified as level 2
(abundant), level 1 (present) or level 0 (absent). DNA flow
cytometry was performed on cell suspensions prepared from
formalin fixed paraffin blocks, available in 86 cases. The
suspensions were preparing using the method described
by Hedley et al. (1983) with minor modifications
(Camplejohn & Macartney, 1985). Briefly, 40pm sections
(usually one section per case) were cut, dewaxed in xylene
and rehydrated through a series of alcohols into water. The
sections were then treated for 30min at 37°C in a 5mgml-1
solution of pepsin (Sigma, Dorset, UK) at pH 1.5. The
resulting suspension was spun at 2,000rpm for 3min and
resuspended in 2.5ml of Isoton (Coulter Electronics, Luton,
UK) containing 1 pgml - I DAPI (4',6-diamidino, -2
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phenylindol dihydrochloride, Boehringer, West Germany).
The suspensions were passed through a 25 gauge needle
before filtration through 35pm pore size polyester gauze.
Samples were analysed with a Becton Dickinson FACS
Analyser (see Camplejohn & Macartney, 1985). To construct
each histogram at least 10,000 cells were scanned and the
results stored on disc for further study. The DNA index was
determined for each case. The DNA index is calculated by
measuring the position of any aneuploid GI peak relative to
the normal GO/GI peak. A DNA index of 1.0 indicates the
presence of only diploid cells. S-phase fractions were
calculated by the method of Baisch et al., (1975). For DNA
aneuploid tumours the S-phase fraction of DNA aneuploid
tumour cells was calculated and expressed as a percentage of
total DNA aneuploid cells. There are well-recognised
problems in the calculation of S-phase fractions in both
DNA diploid and aneuploid tissues, and caution must be
exercised in interpreting such data. Despite these limitations,
many published studies have shown that the values generated
can have biological and clinical significance. For example, in
non-Hodgkin's lymphoma S-phase estimates calculated in this
manner are associated with prognosis (Macartney et al.,
1986) and in breast cancer are associated with epidermal
growth factor expression and tumour grade (Walker &
Camplejohn, 1986). For tumours with multiple DNA
aneuploid populations, no S-phase calculations were
attempted. A full peak coefficient of variation for the GO/GI
peak was calculated for each sample using software supplied
by Becton Dickinson.
Results
Objective response was seen in 56 of the 125 patients (45%).
There was no significant difference in the response rate of
the lobular (47%) and the histological grade 2 (49%) and 3
(42%) ductal carcinomas. However, none of the 4 well
differentiated grade 1 ductal tumours responded (Table I).
Tumours with abundant elastosis were more likely to
respond (100%) than those with some (49%) or no (29%)
elastosis; P<0.01, chi-squared test with 2 degrees of freedom
(Table I).
DNA ploidy was assessable (coefficient of variation range
3.0-7.7, mean 5.1) in 76/86 (88%) of the tumours studied, 16
(21%) of which were diploid and 60 (79%) DNA aneuploid.
Response to chemotherapy was observed in 11/16 (69%)
diploid compared with 27/60 (45%) DNA aneuploid tumours
(chi-squared with Yates' correction= 1.98, not significant at
5% level). The proportion of DNA aneuploid cells within
each tumour was classified as low (<30%), moderate (30-
60%) or high (>60%). Response to chemotherapy was
observed in 9/17 (53%) of the tumours with a low fraction
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Table I Summary of the number and proportion of patients
responding to each form of chemotherapy, subdivided according to
the features studied
Treatment outcome
No response Regression %Regression
Therapy
Adriamycin 30 25 25/55(45%)
Adriamycin+vincristine 39 31 31/70(44%)
Tumour grade
Lobular 8 7 7/15(47%)
1 4 0 0/4 (0%)
2 32 31 31/63(49%)
3 25 18 18/43(42%)
Elastosis
0 17 7 7/24(29%)
1 38 37 37/75(49%)
2 0 7 7/7(100%)
DNA ploidy
Diploid 5 11 11/16(69%)
Aneuploid 33 27 27/60(45%)
%DNA aneuploid cells
Low 8 9 9/17(53%)
Medium 18 13 13/31(42%)
High 4 5 5/9 (56%)
%S-phase cells
Low 6 8 8/14(57%)
Medium 16 17 17/33(52%)
High 10 12 12/22(55%)
Table II Summary of the number of each histological grade of
tumour, subdivided according to their elastosis content, DNA ploidy
and percentages of DNA aneuploid and S-phase cells
Tumour grade
Lobular 1 2 3 %Grade 3
Elastosis
0 2 1 12 9 9/22(41%)
1 8 3 36 28 28/67(42%)
2 1 0 4 2 2/6 (33%)
DNA ploidy
Diploid 4 0 11 1 1/12 (8%)
Aneuploid 2 2 24 32 32/58(55%)
%DNA aneuploid cells
Low I 1 9 6 6/16(38%)
Medium 1 1 11 18 18/30(60%)
High 0 0 2 7 7/9 (78%)
%S-phase cells
Low 3 1 9 1 1/11 (9%)
Medium 3 1 16 13 13/30(43%)
High 0 0 6 16 16/22(73%)
of DNA aneuploid cells, compared with 13/31 (42%) in the
moderate category and 5/9 (56%) in the high category. The
proportion of S-phase cells in each tumour was classified as
low (0-7%), moderate (7.1-14%) or high (greater than-14%).
Response to chemotherapy was observed in 8/14 (57%) of
the tumours with a low fraction of S-phase cells, compared
with 17/33 (52%) of those in the moderate and 12/22 (65%)
in the high categories.
Poorly-differentiated grade 3 tumours were more likely
(see Table II) to be DNA aneuploid (P<0.01, chi-squared
test with Yates' correction, comparing grade 3 with grades I
and 2 combined), have a high proportion of DNA aneuploid
cells (chi-squared=4.59, not significant at 5% level with 2
degrees of freedom comparing the grade 3 tumours with
Table III The numbers of tumours containing no, some or
abundant elastosis, subdivided according to their DNA ploidy and
percentages of DNA aneuploid and S-phase cells
Elastosis
0 1 2 %CategoryO
DNA ploidy
Diploid 2 13 1 2/16(13%)
Aneuploid 13 43 4 13/60(22%)
%DNA aneuploid cells
Low 4 11 2 4/17(24%)
Medium 7 21 2 7/30(23%)
High 1 8 0 1/9 (11%)
%S-phase cells
Low 0 13 1 0/14 (0%)
Medium 8 22 3 8/33(24%)
High 5 16 1 5/22(23%)
grades 1 and 2 combined) and S-phase cells (P<0.01, chi-
squared test with 2 degrees of freedom comparing grade 3
tumours with grades 1 and 2 combined). However, these
features were not associated with the elastosis content of the
tumours (Table III). Of the diploid tumours, 10/16 had a
low fraction (<7%) of S-phase cells, compared with only
4/53 of the DNA aneuploid tumours (P<0.001, chi-squared
test with 2 degrees of freedom).
Discussion
An accurate means of selecting patients who will benefit
from chemotherapy is still needed. Associations between
response and both thymidine labelling indices and drug
sensitivity in the human tumour stem cell assay have been
reported, but both these techniques have pratical limitations
and are not used routinely. Oestrogen receptor status has no
predictive value for response to chemotherapy (Stewart et
al., 1984).
In this study we show that histological grade has no
predictive value. Elastosis is associated with response, but is
of inadequate specificity to assist management. DNA ploidy
was studied in a small number of tumours, but again there
was no indication that this technique could be applied to the
problem of patient selection.
Well-differentiated tumours, with the exceptions of
lymphoma and chronic lymphocytic leukaemia, are relatively
resistant to chemotherapy (Whitehouse, 1984). None of the
four grade I tumours in this study responded to
chemotherapy. However, well-differentiated breast tumours
tend to be diploid (Friedlander et al., 1984), yet a higher
response rate was observed in the diploid tumours. The
trend towards better response to chemotherapy in this group
of tumours may reflect the greater ability of the more
anaplastic tumours to acquire drug resistance, as suggested
by Goldie and Coldman (1984). In contrast, there are some
studies that indicate that poorly-differentiated tumours are
more likely to respond to chemotherapy (Whitehouse, 1984),
although this did not apply to the patients in this study. The
interrelationships between tumour DNA ploidy, growth rate,
fraction of S-phase cells and histological differentiation in
relation to response to chemotherapy need further study.
In summary, we have been unable to demonstrate that
histological grade, elastosis or DNA ploidy significantly
assist the selection of patients with advanced breast cancer
for chemotherapy.
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